Treatment-Resistant Bipolar Depression

The short version

●Bipolar depression is the depressive phase of bipolar disorder; it accounts for most of the time people with bipolar spend unwell and is often harder to treat than mania.
●It is considered treatment-resistant when depression persists despite adequate trials of mood stabilizers (lithium, lamotrigine) and evidence-based atypical antipsychotics.
●Antidepressants are used cautiously, if at all — used alone they can destabilize mood or trigger mania.
●Ketamine has randomized evidence in bipolar depression: a controlled add-on trial showed rapid improvement when given on top of a mood stabilizer.¹ ²
●The crucial safety point: ketamine for bipolar depression is given with mood-stabilizer cover and specialist oversight, never as a standalone antidepressant.
●This is a real but nuanced use — appropriate for the right, stabilized patient, not a blanket recommendation.

Clinical definition

Bipolar depression refers to a major depressive episode occurring in bipolar I or II disorder. Treatment resistance is generally defined as inadequate response to adequate trials of established treatments — lithium, lamotrigine, quetiapine, lurasidone, cariprazine, or olanzapine-fluoxetine — at adequate dose and duration. Bipolar depression differs fundamentally from unipolar depression in management because the underlying illness carries a risk of mania: unopposed antidepressants can precipitate manic or mixed states or accelerate cycling, so mood stabilization is the foundation, and any additional antidepressant strategy is layered on top with care.

How it differs from related conditions

vs. Treatment-resistant depression

Same apparent symptoms, but the bipolar diathesis changes everything — mood stabilizers are central, and antidepressant/ketamine use must be protected against destabilization.

vs. Bipolar 2 depression

The depressive episodes of bipolar II specifically; treatment resistance can occur in either bipolar I or II.

vs. Active mania

The opposite pole, where ketamine is contraindicated; treatment-resistant bipolar depression concerns the depressive phase, with mania risk managed by stabilizers.

First-line treatments

Mood stabilizers (lithium, lamotrigine)

Foundational; lithium also carries anti-suicidal benefit, lamotrigine targets the depressive pole.

Evidence-based atypical antipsychotics

Quetiapine, lurasidone, and cariprazine have specific bipolar-depression evidence.

Cautious, protected antidepressant use

Only with mood-stabilizer cover, and avoided in those prone to mania or rapid cycling.

Psychotherapy + rhythm regulation

IPSRT, CBT, and sleep/routine stabilization support the medication foundation.

When standard treatments fail

For bipolar depression resistant to optimized mood stabilizers and antipsychotics, specialist options include lithium optimization, combinations, ECT (highly effective for severe bipolar depression), and rapid-acting glutamatergic treatment. Intravenous ketamine has randomized add-on evidence in bipolar depression, always on a mood-stabilizer foundation. This is specialist territory where the mania risk is actively managed.

Where ketamine fits

Bipolar depression is one of the few areas where ketamine has dedicated randomized evidence outside unipolar depression: a controlled add-on trial found a single infusion produced rapid antidepressant effects in treatment-resistant bipolar depression,¹ with replication.² Crucially, in those trials ketamine was given on top of a therapeutic mood stabilizer (lithium or valproate) — that mood-stabilizer cover is what makes it appropriate, because ketamine, like other antidepressant treatments, could otherwise risk destabilizing mood. So ketamine here is a real option, but a protected one: for a stabilized bipolar patient under specialist care, not a standalone treatment, and never when mood is elevated. The CANMAT/ISBD framework anchors the underlying bipolar management.³

Where this fits with Tovani

This is a nuanced use that requires confirmed mood-stabilizer treatment and careful screening. Tovani screens for bipolar history and mood elevation precisely because ketamine must not be given as an unopposed antidepressant in bipolar disorder. For a patient with well-managed bipolar disorder on a mood stabilizer whose depression remains resistant, ketamine may be discussed as part of a plan coordinated with the prescriber managing the bipolar illness. An unstable picture, or current or recent mania, is screened out.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Is ketamine safe for bipolar depression?

It can be, but only with mood-stabilizer cover and specialist oversight. The randomized trials gave ketamine on top of lithium or valproate. Given as a standalone antidepressant in bipolar disorder, ketamine — like other antidepressants — could risk destabilizing mood, so it is never used that way or when mood is elevated.

Does ketamine work for bipolar depression?

There is randomized evidence that it does: a controlled add-on trial showed rapid improvement, with replication. It is one of the few areas beyond unipolar depression with dedicated trial support — but always as an add-on to a mood stabilizer.

Why are antidepressants risky in bipolar disorder?

Used without a mood stabilizer, they can trigger manic or mixed episodes or speed up cycling. That is why mood stabilizers are the foundation and why any antidepressant strategy — including ketamine — is layered on carefully.

Can Tovani treat my bipolar depression?

Possibly, if your bipolar disorder is well-managed on a mood stabilizer and your depression remains resistant — coordinated with the prescriber managing your bipolar illness. We screen for mood elevation and bipolar history for safety, and current or recent mania is screened out.

References

Diazgranados N et al. 2010, Archives of General Psychiatry — Randomized add-on trial of an NMDA antagonist (ketamine) in treatment-resistant bipolar depression. (PMID 20679587)
Zarate CA et al. 2012, Biological Psychiatry — Replication of ketamine's antidepressant efficacy in bipolar depression. (PMID 22297150)
Yatham LN et al. 2018, Bipolar Disorders — CANMAT/ISBD guidelines for the management of bipolar disorder. (PMID 29536616)

Last reviewed by Dr. Ben Soffer, DO on June 2, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.